Member Info for Soupdragon78

Chas, Seegene are the only ones with approval in S.Korea and can produce 100,000 kits per day.

AngryAnt, to me it sounds like they've been delaying to save face. The Trump administration has been desperately trying to shut down the CDC for a while and word has it they're not wanting to admit there is a problem.

AngryAnt, the CDC developed their Coronavirus test on a Qiagen PCR and started testing on 1/21. On 1/25 they ordered more Qiagen, stating it was the only machine they could use. By 2/4 they were telling labs to use the CDC test kit with a Applied Biosystems 7500, which obviously failed.

CDC have since purchase more Qiagen equipment which has been installed and calibrated about two weeks ago and its likely they are validating the equipment hence the delay. Although they could be testing and we don't know it.

Nice Simon, what price does that rise sit at?

Atisha, yes it does. CDC has been buying up Qiagen equipment since the start of the month.

If Matt Hancox is endorsing it then stay well away. The mans beyond useless.

Well said investopean.

To much dross talked on here from both sides. Its almost as if they haven't a clue what they are talking about.

Pbb, there not all buys

Watching2, indeed, but the problem is they are there with approval supplying the market already and can produce 100,000 tests per day.
At the minute can NCYT actually sell in Korea other than the research kit?

Watching, Seegene test is CE approved.

Arc, NFX has greater potential. NCYT is valued at £100m which is fair given the quantities they are likely to sell. Its good to ride the wave of the trade over there.

NCYT product is limited, it isn't patented and once a quicker accurate test comes available then its market lead disappears (Qiagen already have a 1 hour test which beats NCYT but has to run on Qiagen equipment), whereas NFX has a patent and can secure market share so that others cannot do the same. Hence it has greater long term value.

Or one of the eleven other kits will be used.

Watch out for those doing syndromic testing.

FSA, its level with France so no issue there.

Comek, Roche are a global company who sell their products everywhere, hence they have a platform.

Novacyt have designed a product that can be used on one of Roche’s products and has been validated by Roche, I.e they’ve tested it and said all is good.

That doesn’t mean Roche are going to sell it, that means that Novacyt can say in their literature that the test is compatible with the LightCycler.

They have also validated it with two other thermal cycler manufacturers, does that mean a JV with those as well?

Imagine you invent a new tyre for cars, you would want Ford, Toyota etc to validate it works with their car as it makes it more attractive to your market, it doesn’t mean ford will start selling your tyres.

Thanks for the correction B2H.

Also see page two of the NCYT CE marked test handbook for compatable thermal cyclers. This allows the test to be used without always buying new cyclers.

https://www.genesig.com/assets/files/Path_Coronavirus_COVID_19_CE_IVD_IFU_Issue_10.pdf?timestamp=1582360300

Comek, she is talking about validation of the test using the Roche LightCycler thermal cycler.

It’s also been validated by Applied Biosystems and Bio-Rad.

It’s not a JV. It about product testing.

It’s about compatibility with PCR platforms that can provide the reading for the test.
Novacyt have tested the product with Roche Lightcycler 480 II and also Applied Biosystems PCR 7500 and Bio-Rad CFX96.

Novacyt don’t make equipment to run the test so they have to ensure that it can be undertaken on standard thermal cyclers.

Stocks true.

Novacyt are more like this...

https://youtu.be/TOAPUcxpBOk

;)

https://youtu.be/uOUfOztcNXI

Its the section 564 which then allows the FDA to assess for EUA's which they are doing and Novacyt have said is happening.

Companies can then submit for an EUA but must await approval before their product can be used.

The CEO even said it on CNN yesterday!